Murphy & Mullick Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Murphy & Mullick Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7K	Buy	265 +6	+2%	+$1.03K	0.03%	297
2025 Q4	$43.7K	Buy	259 +7	+3%	+$1.14K	0.03%	304
2025 Q3	$38.3K	Buy	252 +6	+2%	+$819	0.03%	311
2025 Q2	$31.7K	Buy	246 +12	+5%	+$1.47K	0.03%	324
2025 Q1	$29.9K	Sell	234 -31	-12%	-$4.2K	0.03%	319
2024 Q4	$35K	Buy	+265	New	+$37.3K	0.03%	300

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Murphy & Mullick Capital Management's IBB Position: Q1 2026 in Review

Murphy & Mullick Capital Management increased its iShares Biotechnology ETF (IBB) stake by 2.3% in Q1 2026, buying an estimated $1.03K and bringing the position to 265 shares worth $44.7K. The position accounts for 0.03% of the portfolio, ranked #297.

Murphy & Mullick Capital Management first reported a position in IBB in Q4 2024 and has held it in 6 quarters since. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Murphy & Mullick Capital Management held 265 shares of iShares Biotechnology ETF worth $44.7K as of Q1 2026.
Murphy & Mullick Capital Management bought 6 iShares Biotechnology ETF shares in Q1 2026, an estimated $1.03K.
iShares Biotechnology ETF made up 0.03% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #297 holding.
Murphy & Mullick Capital Management first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 6 quarters since.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.